

## Special Issue

# Oesogastric Cancer: Treatment and Management

### Message from the Guest Editor

Despite recent advances in the management of oesogastric cancers through the optimization of chemotherapy and radiotherapy protocols and surgical procedures, these cancers remain fatal in a large number of situations, with an average survival of 16% at 5 years. One-third of patients are operable at the time of diagnosis. This Special Issue aims to show the precise impact of the most recent evolutions in terms of operative techniques in initial or recurrence settings, for example, the contribution of minimally invasive surgery—including thoracic approaches—on the quality of the lymph node resection, its extension, survival data, etc.

- Investigate the possibilities of improving the postoperative course in vulnerable patients by medical of interventional perioperative optimization according to comorbidities.
- Describe the surgical possibilities, novelties, and limits in the situation of peritoneal carcinosis.
- Evaluate the contribution of new chemotherapy/immunotherapy/radiotherapy protocols.
- Explore the management of complete responders.

I look forward to receiving your contributions.

---

### Guest Editor

Dr. Arnaud Pasquer

Service de Chirurgie Digestive, CHU Lyon, Lyon, France

---

### Deadline for manuscript submissions

closed (31 December 2024)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/147241](https://mdpi.com/si/147241)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)